⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934164 | 1.00 | — | — | |
| SCHEMBL7510389 | 0.90 | — | — | |
| SCHEMBL6936137 | 0.90 | — | — | |
| SCHEMBL6943087 | 0.83 | — | — | |
| SCHEMBL7505843 | 0.82 | MAPK1 (0.43) | — | |
| SCHEMBL7500890 | 0.80 | — | — | |
| SCHEMBL6942199 | 0.80 | — | — | |
| SCHEMBL6937052 | 0.80 | KDM4E (0.57) | — | |
| SCHEMBL6936621 | 0.80 | KDM4E (0.57) | — | |
| SCHEMBL7515959 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| JP-3113678-B2 | — | — | 2000-12-04 | — | — | JP | claimed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | claimed |
| EP-0600950-B1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | claimed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1993004052-A1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| US-5693657-A | USEFUL FOR TREATING HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |